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Cervical cancerAbstract A newMannich base series of piperazine linked berberine analogues was furnished in this
study to screen the antioxidant and anticancer potential of the resultant analogues. Alkoxy group at a
C-9 position of berberine was converted to hydroxyl functionality to enhance the ability of final scaf-
folds binding to the target of drug action mainly through hydrophobic effect, conjugation effect,
whereasMannich base functionality was introduced on the C-12 position of berberine. Scaffolds were
investigated for their free radical scavenging antioxidant potential in FRAP and DPPH assay,
whereas tested to check their Fe+3 reducing power in ABTS assay. The radical scavenging potential
of the final derivatives 4a–jwas found excellent with IC50s,<13 lg/mL and< 8 lg/mL inDPPHand
ABTS assay, respectively, whereas some analogues showed significant Fe+3 reducing power with
absorption at around 2 nm in the FRAP assay. Anticancer effects of titled compounds were inspected
against cervical cancer cell lineHela andCaski adapting SRB assay, in which analogues 4a–j presented
<6 lg/mL of IC50s, and>30 of therapeutic indices, thus exerting low cytotoxic values against Malin–
Darby canine kidney (MDCK) cell lines at CC50s>125 lg/mL.Hence, from the bioassay outcomes it
can be stated that these analogues are dual active agents as the scavengers of reactive oxygen species
and inhibitors of the cancerous cells as compounds with halogen functional group have overall good
pharmacological potential in assays studied in this research. Correct structure of the final compounds
was adequately confirmed on the basis of FT-IR and 1H NMR as well as elemental analyses.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Reactive oxygen species (ROS) carrying an unpaired electron
in an atomic orbital are endogenous stimuli capable to interact
with DNA which is the primary reason for the occurrence
of cancer (Valko et al., 2004). One of the reasons for the
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high reactivity is some kind of pathological states and
physiochemical circumstances. These species can accept or
donate an electron with adjunct molecules and can act as
oxidants or reductants, important in the pathogenesis of many
different diseases (Droge, 2002; Valko et al., 2006, 2007;
Cheeseman and Slater, 1993). Interaction of ROS with DNA
results into the damage of cell and homeostatic disruption
which may outcomes into deleterious events such as cardiovas-
cular disorders, diabetes, cancer, cirrhosis etc. (El-Gazzar
et al., 2009; Kashif et al., 2008). ‘‘Oxidative stress” which is
an imbalance toward the pro-oxidative state is the responsible
factor to damage very important biological components
like essential proteins, lipids and nucleic acids (Lobo et al.,
2010) thereby furnishing excess quantities of reactive oxygen
species. The process of cancer and its treatments create
an discrepancy between anti-oxidant protection and toxic
production.
Antioxidants can reduce oxidative stress caused carcino-
genesis by an immediate scavenging of ROS and have an
important role in the enhancement of these infected condi-
tions. They are stable components and able to donate an elec-
tron to unstable ROS, and thus ROS can be neutralized and
can no longer affect essential biological species (Mc Cord,
2000). The chain reactions often constructed by ROS can be
broken by antioxidant molecules by the donation of an
electron which stops catalysts of ROS which initiated chain
reactions and as a result ROS can be quickly destroyed. By
such means, antioxidant molecules works as an enzyme
inhibitor, a radical scavenger, singlet oxygen quencher, hydro-
gen and electron donor, peroxide decomposer, synergist,
and metal-chelating agents (Rice-Evans and Diplock, 1993;
Krinsky, 1992). The aforementioned facts imply that scaffolds
which hold dual antioxidant and anticancer activities are of
tremendous significance in the current medication finding
improvement. In fact, discovery of anticancer molecules from
natural product leads is a major theme of the current decade
worldwide with a reason that cancer is responsible for numbers
of deaths in most developed, developing and underdeveloped
countries.
Cancer is responsible for numbers of death each year
worldwide, more specifically with the highest death rate in Asia
and then Europe. As per the World Health Organization,
death rate were 6.2 million in 1997 and 7.6 million in 2008,
which means 13% of all fatalities were due to melanoma and
that the international melanoma rate may improve by 50%
to 15 million new cases by 2030. Among women, cervical
cancer is the most typical which is responsible for an approx-
imated 527,624 new cases and 265,653 fatalities in 2012.
Cervical melanoma is the 2nd most typical females’ melanoma
in females older 15 to 44 years in Globe (Bray et al., 2013).
Despite the improvement in the area of melanoma research,
both developing and developed countries are in the hold of this
dangerous illness and still there is a need to discover and create
therapeutic agents potentially effective against several types of
cancer. It has identified that natural products signify the
wealthiest source of high substance variety, offering the foun-
dation for recognition of novel scaffolding components that
provides starting points for rational drug design (Koehn and
Carter, 2005). Natural products are small-molecule secondary
metabolites that contribute to organism survival. This can be
one of the factors that initiatives have been instructed to findappealing cancer therapeutic agents from natural resources.
According to the latest evaluation, 49% of cancer medication
was either through natural products or their derivatives that
are used as chemotherapeutic drugs (Newman and Cragg,
2012). The latest review states that there are 12 approved
natural product anticancer agents (Basmadjian et al., 2014).
Berberine, an isoquinoline plant alkaloid is acquired from
different plant species including Hydrastis canadensis L.,
(Ranuncufaceae), Berberineeris species (Berberidaceae) and
Arcungelisia flaw (Menispermaceae). Reports show that ber-
berine has been observed to be efficient towards osteosarcoma,
lung, liver, prostate and breast cancer (Wang et al., 2011; Patil
et al., 2010) by using transcriptional control of some oncogene
and carcinogenesis-related gene appearance and contacts with
both DNA and RNA. It regulates ROS production and
activates nuclear factor-B that make it responsible for the
inhibitor of cancer cell growth because it affects N-
acetyltransferase, cyclooxygenase-2, and topoisomerase activi-
ties and gene/protein expression. Berberin has efficacies as the
most potent anticancer natural product alkaloid as it inhibits
tumourigenic microorganisms, regulates oncogene and
carcinogenesis-related gene expression, inhibits telomerase,
inhibits cyclooxygenase-2, suppresses tumour cell prolifera-
tion, impacts cytochrome c discharge and caspase initial as
well as enhances the possibilities of fighting against multidrug
resistance problems (Sun et al., 2009). Naturally occurring
berberine as well as their synthetic analogues have been shown
to demonstrate interesting and different activities including
antimicrobial, antileukemic, anti ulcerous, and enzyme-inhibiting,
anti-inflammatory, anti-diarrhoea, glucose-lowering, cholesterol-
lowering, neuroprotective, antidepressant, Alzheimers disease-
ameliorating (Verpoorte, 1998; Bodiwala et al., 2011; Kuo et al.,
2004; Yin et al., 2002; Leng et al., 2004; Peng et al., 2007; Cui
et al., 2009; Kulkarni and Dhir, 2007; Asai et al., 2007) etc. It
exhibits activity on LDLR (Yang et al., 2008) and is found to
reveal cytotoxicity against HeLa, SVKO3, Hep-2 cancer cell
lines (Orfila et al., 2000) and anti-leishmaniasis activity
(Vennerstrom et al., 1990). Thus, in a view of the above-
mentioned therapeutic role of berberine, their scaffolds have
attracted significant interest in recent years.
Recent reports suggest that this piperazine derivative
effectively prevents melanoma cell growth and causes
caspase-dependent apoptosis via suppressing multiple
signalling pathways implicated in cancer (Edward and
Zhonglin, 2013). Moreover, alkaloids bearing piperazine resi-
due are previously studied to deliver significant anticancer
effects (Kohmoto et al., 1988). Some recent reports suggested
that substituting different electron withdrawing and electron
donating functional group bearing piperazine moieties to
the heterocyclic or aromatic core results in analogues demon-
strating appreciable anticancer efficacies (Patel and Park,
2013; Patel et al., 2011). According to the extensive variety
of scientific actions associated with berberine and the
piperazine, the mixture of these two moieties in the same
compound is an exciting task for the growth of new
pharmacologically effective agents. Derivatization has been
conducted via developing N-Mannich bases as the scientific
results of this scaffold is well known, particularly as antiox-
idant (Malhotra et al., 2012; Ma et al., 2013; Dong et
al., 2012) and anticancer agents (Bala et al., 2014;
Venkateshwarlu et al., 2014). N-Mannich bases equipped
with piperazine linkage was recently attempted and adapted
38 B. Mistry et al.in the present study for the effective synthesis of berberine-
piperazine systems (Patel et al., 2012).
2. Experimental section
2.1. Materials and methods
Highest quality chemicals and reagents were used in this study
without prior purification. Veego Open capillary electronic
apparatus VMP-D was utilized to obtain melting points of
the synthesized compounds that were uncorrected. Shimadzu
8400-S FT-IR spectrophotometer (KBr pellets) and Varian
500 MHz model spectrometer (DMSO as a solvent and TMS
as internal standard) were used to obtain FT-IR and 1H
NMR spectra of the title compounds. TLC was carried out
using appropriate mobile phase systems n silica gel-G coated
microscopic glass slides (2  7.5 cm), and TLC spots were
observed in UV light chamber. FT-IR bands were presented
in cm1 as well as 1H NMR spectral results were furnished
in ppm downfield from TMS with s, singlet; d, doublet; m,
multiplet and br s, broad singlet patterns. Elemental analyses
(C, H, N) were done using a Heraeus Carlo Erba 1180 CHN
analyzer.
2.2. General procedure for the synthesis of berberrubine (2)
Berberine hydrochloride (10 g, 0.01 mol) was included to a
50 mL round bottom flask. The reaction system was main-
tained at reduced pressure (20–30 mmHg) applying an oil
pump, and warmed to 190 C followed by reacting for
40 min. The vacuum pump was turned off after the tempera-
ture decreased to room temperature. The reaction product
was purified using silica gel column chromatography (CHCl3/
CH3OH:15:1 and 10:1, eluting until no compound was seen in
the eluent) to acquire a brownish red amorphous powder com-
pound 2 (6.6 g, 85%).
2.2.1. General procedure for preparation of compounds (4a–j)
Compound 2 (0.5 g, 0.01 mol) was dissolved in 25.0 mL of the
anhydrous ethanol, various piperazine derivatives (0.015 mol)
and formaldehyde aqueous solution (37%, 0.05 mol) were
added, stirred at room temperature or at 80 C for 24 h. It
was then concentrated under reduced pressure to give the
crude product, which was purified using flash silica gel column
chromatography (CH2Cl2/MeOH= 20:1) to obtain the final
compound.2.2.1.1. 12-(1-(4-Methylphenyl)piperazine-1-ylmethyl)-berber-
rubine (4a). Light yellow solid, Yield: 65%. m.p. 264–266 C.
IR (KBr) cm1: 3623 (OH), 3042 (C–H, Ar), 1630–1533
(C‚C, Ar), 1242 (Ar–N). 1H NMR (500 MHz, Chloroform)
d 9.79 (s, 1H, –OH of berberine ring), 9.42 (s, 1H, H-8), 7.89
(s, 1H, H-13), 7.44 (s, 1H, H-1), 7.05 (s, 1H, H-4), 6.90–6.71
(m, 4H, Ar–H, piperazine H-22, H-23, H-25, H-26), 6.22 (s,
2H, –OCH2O), 6.03 (s, 1H, H-11), 5.78 (t, J= 5.5 Hz, 2H,
H-6), 4.11 (s, 2H, CH2, H-14 Mannich base), 3.97 (s, 3H,
OCH3), 3.84 (br s, 4H, piperazine, H-18, H-20), 3.22 (br s,
4H, piperazine, H-15, H-17), 3.05 (t, J=5.4 Hz, 2H, H-5), 1.95
(s, 3H, Ar–CH3 of piperazine). Anal. Calcd. for C31H32ClN3O4:
C, 68.19; H, 5.91; N, 7.70. Found: C, 68.25; H, 5.98; N, 7.81.2.2.1.2. 12-(1-(2-Chlorophenyl)piperazine-1-ylmethyl)-berber-
rubine (4b). Light yellow solid, Yield: 70%. m.p. 271–272 C.
IR (KBr) cm1: 3642 (OH), 3049 (C–H, Ar), 1628–1545
(C‚C, Ar), 1239 (Ar–N), 778 (C–Cl). 1H NMR (500 MHz,
Chloroform) d 9.85 (s, 1H, –OH of berberine ring), 9.44 (s,
1H, H-8), 7.92 (s, 1H, H-13), 7.31 (s, 1H, H-1), 7.11 (s, 1H,
H-4), 6.86–6.66 (m, 4H, Ar–H, piperazine H-22, H-23, H-24,
H-25), 6.29 (s, 2H, –OCH2O), 6.06 (s, 1H, H-11), 5.86 (t,
J= 5.4 Hz, 2H, H-6), 4.09 (s, 2H, CH2, H-14 Mannich base),
3.87 (s, 3H, OCH3), 3.75 (br s, 4H, piperazine, H-18, H-20),
3.31 (br s, 4H, piperazine, H-15, H-17), 3.17 (t, J= 5.3 Hz,
2H, H-5). Anal. Calcd. for C30H29Cl2N3O4: C, 63.61; H,
5.16; N, 7.42. Found: C, 63.42; H, 5.24; N, 7.27.
2.2.1.3. 12-(1-(3-Chlorophenyl)piperazine-1-ylmethyl)-berber-
rubine (4c). Light yellow solid, Yield: 63%. m.p. 253–255 C.
IR (KBr) cm1: 3637 (OH), 3051 (C–H, Ar), 1631–1551
(C‚C, Ar), 1244 (Ar–N), 757 (C–Cl). 1H NMR (500 MHz,
Chloroform) d 9.92 (s, 1H, –OH of berberine ring), 9.49 (s,
1H, H-8), 7.86 (s, 1H, H-13), 7.35 (s, 1H, H-1), 7.10 (s, 1H,
H-4), 6.77–6.54 (m, 4H, Ar–H, piperazine H-22, H-23, H-24,
H-26), 6.31 (s, 2H, –OCH2O), 6.04 (s, 1H, H-11), 5.80
(t, J= 5.5 Hz, 2H, H-6), 4.02 (s, 2H, CH2, H-14 Mannich
base), 3.85 (s, 3H, OCH3), 3.71 (br s, 4H, piperazine, H-18,
H-20), 3.25 (br s, 4H, piperazine, H-15, H-17), 3.07 (t,
J= 5.5 Hz, 2H, H-5). Anal. Calcd. for C30H29Cl2N3O4: C,
63.61; H, 5.16; N, 7.42. Found: C, 63.78; H, 5.04; N, 7.68.
2.2.1.4. 12-(1-(4-Chlorophenyl)piperazine-1-ylmethyl)-berber-
rubine (4d). Light yellow solid, Yield: 72%. m.p. 259–261 C.
IR (KBr) cm1: 3648 (OH), 3043 (C–H, Ar), 1625–1543
(C‚C, Ar), 1236 (Ar-N), 784 (C–Cl). 1H NMR (500 MHz,
Chloroform) d 9.80 (s, 1H, –OH of berberine ring), 9.51
(s, 1H, H-8), 7.88 (s, 1H, H-13), 7.39 (s, 1H, H-1), 7.06 (s,
1H, H-4), 6.81–6.59 (m, 4H, Ar-H, piperazine H-22, H-23,
H-25, H-26), 6.23 (s, 2H, –OCH2O), 6.15 (s, 1H, H-11), 5.82
(t, J= 5.3 Hz, 2H, H-6), 3.96 (s, 2H, CH2, H-14 Mannich
base), 3.89 (s, 3H, OCH3), 3.77 (br s, 4H, piperazine, H-18,
H-20), 3.32 (br s, 4H, piperazine, H-15, H-17), 3.11 (t,
J= 5.5 Hz, 2H, H-5). Anal. Calcd. for C30H29Cl2N3O4: C,
63.61; H, 5.16; N, 7.42. Found: C, 63.50; H, 5.17; N, 7.55.
2.2.1.5. 12-(1-(2-Fluorophenyl)piperazine-1-ylmethyl)-berber-
rubine (4e). Light yellow solid, Yield: 66%. m.p. 228–230 C.
IR (KBr) cm1: 3651 (OH), 3054 (C–H, Ar), 1627–1540
(C‚C, Ar), 1249 (Ar–N). 1H NMR (500 MHz, Chloroform)
d 9.88 (s, 1H, –OH of berberine ring), 9.45 (s, 1H, H-8), 7.80
(s, 1H, H-13), 7.37 (s, 1H, H-1), 7.09 (s, 1H, H-4), 6.87–6.61
(m, 4H, Ar–H, piperazine H-22, H-23, H-24, H-25), 6.28 (s,
2H, –OCH2O), 6.17 (s, 1H, H-11), 5.77 (t, J= 5.4 Hz, 2H,
H-6), 4.07 (s, 2H, CH2, H-14 Mannich base), 3.95 (s, 3H,
OCH3), 3.83 (br s, 4H, piperazine, H-18, H-20), 3.37 (br s,
4H, piperazine, H-15, H-17), 3.20 (t, J= 5.3 Hz, 2H, H-5).
Anal. Calcd. for C30H29ClFN3O4: C, 65.51; H, 5.31; N, 7.64.
Found: C, 65.34; H, 5.19; N, 7.53.
2.2.1.6. 12-(1-(4-Fluorophenyl)piperazine-1-ylmethyl)-berber-
rubine (4f). Light yellow solid, Yield: 69%. m.p. 239–241 C.
IR (KBr) cm1: 3644 (OH), 3045 (C–H, Ar), 1632–1539
(C‚C, Ar), 1251 (Ar–N). 1H NMR (500 MHz, Chloroform)
d 9.93 (s, 1H, –OH of berberine ring), 9.47 (s, 1H, H-8), 7.84
(s, 1H, H-13), 7.40 (s, 1H, H-1), 7.12 (s, 1H, H-4), 6.80–6.57
Berberine moieties as anticancer and antioxidant effects 39(m, 4H, Ar-H, piperazine H-22, H-23, H-25, H-26), 6.32 (s,
2H, –OCH2O), 6.07 (s, 1H, H-11), 5.81 (t, J= 5.4 Hz, 2H,
H-6), 3.95 (s, 2H, CH2, H-14 Mannich base), 3.86 (s, 3H,
OCH3), 3.80 (br s, 4H, piperazine, H-18, H-20), 3.33 (br s,
4H, piperazine, H-15, H-17), 3.08 (t, J= 5.4 Hz, 2H, H-5).
Anal. Calcd. for C30H29ClFN3O4: C, 65.51; H, 5.31; N, 7.64.
Found: C, 69.39; H, 5.42; N, 7.73.
2.2.1.7. 12-(1-(4-Trifluoromethoxyphenyl)piperazine-1-ylmethyl)-
berberrubine (4g). Light yellow solid, Yield: 58%. m.p. 275–
277 C. IR (KBr) cm1: 3652 (OH), 3044 (C–H, Ar), 1626–1535
(C‚C, Ar), 1238 (Ar–N). 1H NMR (500MHz, Chloroform) d
9.95 (s, 1H, –OH of berberine ring), 9.43 (s, 1H, H-8), 7.90 (s,
1H, H-13), 7.42 (s, 1H, H-1), 7.07 (s, 1H, H-4), 6.92–6.68 (m,
4H, Ar-H, piperazine H-22, H-23, H-25, H-26), 6.26 (s, 2H, -
OCH2O), 6.12 (s, 1H, H-11), 5.92 (t, J=5.5 Hz, 2H, H-6), 4.10
(s, 2H, CH2, H-14 Mannich base), 3.96 (s, 3H, OCH3), 3.76 (br
s, 4H, piperazine, H-18, H-20), 3.29 (br s, 4H, piperazine, H-15,
H-17), 3.06 (t, J=5.4 Hz, 2H, H-5). Anal. Calcd. for C31H29-
ClF3N3O5: C, 60.44; H, 4.74; N, 6.82. Found: C, 60.57; H, 4.86;
N, 6.72.
2.2.1.8. 12-(1-(4-Trifluoromethylphenyl)piperazine-1-ylmethyl)-
berberrubine (4h). Light yellow solid, Yield: 55%. m.p. 224–
226 C. IR (KBr) cm1: 3645 (OH), 3052 (C-H, Ar), 1629–1541
(C‚C, Ar), 1240 (Ar–N). 1H NMR (500MHz, Chloroform) d
9.83 (s, 1H, –OH of berberine ring), 9.46 (s, 1H, H-8), 7.78 (s,
1H, H-13), 7.33 (s, 1H, H-1), 7.13 (s, 1H, H-4), 6.91–6.60 (m,
4H, Ar–H, piperazine H-22, H-23, H-25, H-26), 6.30 (s, 2H, –
OCH2O), 6.14 (s, 1H, H-11), 5.77 (t, J=5.5 Hz, 2H, H-6), 4.12
(s, 2H, CH2, H-14 Mannich base), 3.90 (s, 3H, OCH3), 3.78 (br
s, 4H, piperazine, H-18, H-20), 3.26 (br s, 4H, piperazine, H-15,
H-17), 3.09 (t, J=5.3 Hz, 2H, H-5). Anal. Calcd. for C31H29-
ClF3N3O4: C, 62.05; H, 4.87; N, 7.00. Found: C, 62.16; H, 4.96;
N, 7.12.
2.2.1.9. 12-(1-(2-Nitrophenyl)piperazine-1-ylmethyl)-berberru-
bine (4i). Light yellow solid, Yield: 68%. m.p. 261–263 C. IR
(KBr) cm1: 3653 (OH), 3053 (C–H, Ar), 1619–1537 (C‚C,
Ar), 1563 (N–O stretch), 1332 (N–O stretch), 1237 (Ar–N).
1H NMR (500 MHz, Chloroform) d 9.90 (s, 1H, –OH of ber-
berine ring), 9.53 (s, 1H, H-8), 7.74 (s, 1H, H-13), 7.47 (s, 1H,
H-1), 7.04 (s, 1H, H-4), 6.88–6.58 (m, 4H, Ar–H, piperazine H-
22, H-23, H-24, H-25), 6.27 (s, 2H, –OCH2O), 6.08 (s, 1H, H-
11), 5.87 (t, J= 5.3 Hz, 2H, H-6), 4.05 (s, 2H, CH2, H-14
Mannich base), 3.88 (s, 3H, OCH3), 3.72 (br s, 4H, piperazine,
H-18, H-20), 3.27 (br s, 4H, piperazine, H-15, H-17), 3.13 (t,
J= 5.4 Hz, 2H, H-5). Anal. Calcd. for C30H29ClN4O6: C,
62.44; H, 5.07; N, 9.71. Found: C, 62.35; H, 5.18; N, 9.57.
2.2.1.10. 12-(1-(4-Nitrophenyl)piperazine-1-ylmethyl)-berber-
rubine (4j). Light yellow solid, Yield: 63%. m.p. 272–274 C.
IR (KBr) cm1: 3638 (OH), 3039 (C–H, Ar), 1615–1544
(C‚C, Ar), 1526 (N–O stretch), 1341 (N–O stretch), 1235
(Ar–N). 1H NMR (500 MHz, Chloroform) d 9.87 (s, 1H, –
OH of berberine ring), 9.50 (s, 1H, H-8), 7.82 (s, 1H, H-13),
7.49 (s, 1H, H-1), 7.14 (s, 1H, H-4), 6.84–6.55 (m, 4H, Ar-H,
piperazine H-22, H-23, H-25, H-26), 6.25 (s, 2H, –OCH2O),
6.13 (s, 1H, H-11), 5.94 (t, J= 5.3 Hz, 2H, H-6), 4.13 (s,
2H, CH2, H-14 Mannich base), 3.92 (s, 3H, OCH3), 3.79 (br
s, 4H, piperazine, H-18, H-20), 3.24 (br s, 4H, piperazine, H-
15, H-17), 3.08 (t, J= 5.5 Hz, 2H, H-5). Anal. Calcd. forC30H29ClN4O6: C, 62.44; H, 5.07; N, 9.71. Found: C, 62.53;
H, 5.21; N, 9.83.
2.3. Antioxidant capacity by DPPH assay
Radical scavenging efficiency of the compounds examined was
evaluated in vitro by the DPPH analysis. DPPH is among the
few stable and commercially available organic nitrogen radi-
cals. DPPH radicals are considered as an associate method
for the preliminary screening of compounds capable of scav-
enging activated oxygen species, since they are more constant
and easier to deal with than oxygen free radicals and DPPH
assay continues to be commonly used to evaluate the antioxi-
dant action of different phenolic substances. The DPPH solu-
tion contains a deep violet colour. Radical scavenging activity
of antioxidant compounds can be calculated spectrophotomet-
rically at 517 nm. The DPPH radical reveals absorbance at
517 nm, that reduces by the bleaching of a violet coloured
methanol solution upon reduction by an antioxidant or a
radical via hydrogen atom or electron move to the odd
electron in DPPH generating the pale yellow non-radical form
(DPPH-H). This decrease is proportional to the increase of
non-radical forms of DPPH.
The DPPH radical solution was ready by dissolving an
appropriate quantity of DPPH in methanol. The DPPH radi-
cal solution (180 lL) was added to a solution of the compound
to be tested in methanol (20 lL) at various concentrations (0.1,
1, 10 and 100 lg/mL). The mixture was shaken extremely and
incubated at room temperature in the dark for 30 min. The loss
of the absorbance of the causing solution was then calculated
spectrophotometrically at 517 nm. All measurements were
developed in triplicate. Two controls were applied for this test:
a negative control (blank) containing of methanol (20 lL) and
the DPPH radical solution (180 lL) and a positive control
including the referrals anti-oxidant (Ascorbic acid) in metha-
nol and DPPH radical solution. The results of this bioassay,
RSA% (the radical scavenging activity in percentage) was
determined according to Mensor et al. (Mensor et al., 2001;
Mistry et al., 2015) as described in the below equation:
% Scavenging ¼ Absorbance of blankAbsorbance of test
Absorbance of blank
 100
A plot of concentration of test compounds and % scaveng-
ing introduced IC50s in the presence of an Ascorbic acid as
standard.
2.4. Antioxidant capacity by ABTS assay
The second is analysed by the capability of antiradical ele-
ments to satisfy the ABTS+, a blue–green chromophore with
attribute absorption at 734 nm. The inclusion of anti-oxidants
to the conducted radical cation decreases it to ABTS, identify-
ing a decolourization. In this technique, an antioxidant is
included in a pre-formed ABTS radical solution, and after a
set period, the staying ABTS+ is quantified spectrophotomet-
rically at 734 nm (Molyneux, 2004; Mistry et al., 2015). The
ABTS+ was created by responding 7 mM ABTS in H2O with
2.45 mM potassium persulfate (K2S2O8), saved in the dark at
room temperature for 12–16 h before use (the radical was
constant for more than two days under these conditions).
40 B. Mistry et al.The ABTS+ solution was further diluted with methanol until
finally the preliminary absorbance value of 0.70 ± 0.02 at
734 nm at 30 C.
The 1000 lL stock solutions of titled compounds 4a–j was
established upon dissolving them in methanol and further dilu-
tions furnishes 100 lL, 10 lL, 1 lL, and 0.1 lL of quantities of
samples. An amount of 20 lL of each compound solution was
added to 180 lL of diluted ABTS+ solution were mixed in 96
well plates in a dark place which were then incubated for
10 min to measure UV absorption at 734 nm. A mixture of
180 lL ABTS and 20 lL mL methanol was applied as a
control determination while ascorbic acid was applied as a
reference drug. The UV absorption data represented the radi-
cal scavenging rates that give the corresponding IC50s for the
test compounds. All measurements were produced in triplicate
and for every single analysis a fresh ABTS+ stock solution
was prepared.
The scavenging capability of ABTS+ radical was calcu-
lated using the following equation:
% Scavenging ¼ Absorbance of blankAbsorbance of test
Absorbance of blank
 1002.5. FRAP assay
The FRAP assay of the compounds was performed using mod-
ified method as described by Benzie and Strain (Benzie and
Strain, 1999). FRAP assay conducted the in vitro antioxidant
action for all the newly synthesized compounds by the decrease
of a colourless Fe3+-tripyridyltriazine complex into a blue-
coloured Fe2+-tripyridyltriazine complex. The antioxidant
potentials of the compounds were estimated as their power
to reduce the TPTZ–Fe(III) complex to TPTZ–Fe(II) complex,
which is simple, fast, and reproducible. The solutions con-
tained 300 mM acetate buffer (3.1 g C2H3NaO23H2O and
16 mL C2H4O2), pH 3.6, 10 mM TPTZ (2,4,6-tripyridyl-
s-triazine) solution in 40 mM hydrochloric acid and 20 mM
ferric chloride hexahydrate solution. The fresh working solu-
tion was ready by mixing acetate buffer (25 mL), TPTZ
(2.5 mL), and ferric chloride hexahydrate solution (2.5 mL).
The temperature of the solution was raised to 37 C before
use and allowed to react with the FRAP solution (300 lL) in
a volume ratio of 10:1:1, respectively. The 1 mL of methanol
as blank, test samples dissolved in methanol and ascorbic acid
as standard dissolved in water and the reaction was allowed to
run for 30 min. The coloured product (ferrous tripyridyl tri-
azine complex) was monitored at a wavelength of 593 nm.
The experiments were conducted in triplicate, and their mean
was measured for each compound.
2.6. In vitro anticancer bioassay
2.6.1. Cell cultures
Human cervical cancer cell line (HeLa) was keep up in Dul-
becco’s modified Eagle’s medium (DMEM; Gibco-BRL,
Carlsbad, CA, USA) supplemented with 10% heat-
inactivated foetal bovine serum (FBS) and 1% of Antibiotic–
Antimycotic solution (100X). CaSki and MDCK cells were
cultured in RPMI-1640 medium (HyClone) supplemented with
10% FBS, and 1% of Antibiotic–Antimycotic solution (100X).Both of the cells were cultured at 37 C in a 5% CO2
incubator.
The effects of Mannich base berberine derivatives on the
different cell lines were determined by the SRB assay as
described previously (Adaramoye et al., 2011; Mistry et al.,
2015). Briefly, 5  103 cells were incubated in triplicate on a
96-well plate under normal culture conditions overnight.
HeLa, Caski and MDCK were treated with different concen-
trations of Mannich base berberine derivatives (0.1 lL, 1 lL,
10 lL and 100 lL). Untreated cells served as control. After
48 h, cells were fixed with ice-cold 70% (w/v) Acetone
(100 lL/well) for 1 h at 4 C. After incubation, solvent was
removed and plates were dried in an oven at 60 C tempera-
ture. Cells were then stained to the SRB (0.4% w/v in 1%
acetic acid, 100 lL/well) followed by SRB removal and wash-
ing thrice with 1% of acetic acid and dried again under hot air
oven at 60 C. Microscopic observation was carried out to
determine the morphology of the cells. Bound dye was solubi-
lized with 10 mM Tris base (100 lL/well), and absorbance was
read at 540 nm on a plate reader. Spectrophotometric data
were recorded at 510 nm to calculate the inhibition concentra-
tion of 50% (IC50), cytotoxic concentration of 50% (CC50) and
therapeutic index (TI).3. Results and discussion
3.1. Chemistry
The synthesis route of Mannich berberine derivatives was con-
veniently undertaken as outlined in Schemes 1. To begin with,
berberrubine 2 was obtained in 85% of yield through selective
demethylation of berberine hydrochloride 1 at 190 C temper-
ature and 20–30 mmHg pressure (Iwasa et al., 1996) and then
the appropriate piperazine derivatives with formaldehyde were
added, stirred at 80 C or room temperature to obtain the
aminomethylation berberrubine derivatives 4a–j (Bekircan
and Bektas, 2008). The correct formation of the structure of
compounds 4a–j was confirmed by recording the FT-IR, 1H
NMR, Mass spectrometry and elemental analysis (CHN).
The FT-IR spectra of compound 4a–j show the C–H stretching
for aromatics, and C‚C band of aromatics gave an absorp-
tion band at about 3041–3012 cm1 and 1618–1541 cm1. A
single sharp absorption band, attributed to Ar-N bands, was
identified in the 1245–1275 cm1 in Mannich bases along with
sharp chlorine signal at 797–741 cm1. The presence of –OH
group produced a broad absorption band at values 3615–
3658 cm1. The corresponding peak at 1563 cm1 and 1332
which suggests the presence of N–O stretch. In the 1H NMR
spectra of Mannich bases, 4a–j the signals of the respectively
prepared derivatives were verified on the basis of their chemi-
cal shifts, multiplicities, and coupling constants. Compounds
4a–j show singlet peak at around 3.91–4.18 ppm (s, 2H), for
the CH2 group, which confirms the formation of Mannich
bases. The 1H NMR spectrum of berberine ring showed a
singlet at 9.42, 7.89, 7.44, 7.05, and 6.03 ppm for H-8, H-13,
H-1, H-4, and H-11 respectively. Compounds 4a–j displayed
characteristic O–CH2–O signals at around 6.22 ppm
(s, 2H, –OCH2O). Also, a triplet peak was shown at 3.05,
and 5.78 ppm due to H-5 and H-6 proton atoms of berberine
ring. The 1H NMR spectrum of 4a exhibited a sharp singlet
at 1.95 ppm integrating for three protons of the methyl group
N+
O
O
OCH3
OCH3
Cl-
i N+
O
O
OH
OCH3
Cl-
ii
N+
O
O
OH
OCH3
Cl-
1 2
4a-j
Reagents &conditions: i. 190oC, 20-30 mm Hg 40 min: ii. C2H5OH, HCHO, 80oC, 24 h
+
3
H
N
N
R
N
N
R
R 4a 4-CH3
4b 2-Cl
4c 3-Cl
4d 4-Cl
4e 2-F
4f 4-F
4g 4-OCF3
4h 4-CF3
4i 2-NO2
4j 4-NO2
12
3
4 5
6
7 8
9
10
1112
13
14
15 16 17
18
19
20
2122
23
24
25
26
Scheme 1 Synthesis of piperazine linked berberine derivatives.
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H-17) piperazine nucleus were observed as two broad singlets
at around 3.84 ppm as well as 3.22 ppm. Moreover, aromatic
rings linked to the piperazine ring appeared to have a corre-
sponding signal as multiples in the range 6.90–6.71 ppm. The
signal at 9.79 ppm was due to the –OH group present in
berberine ring. All of the novel compounds gave C, H and N
analyses within 0.4 percent points from the theoretical values,
i.e. in an acceptable range.
3.2. Evaluation of biological activities
3.2.1. Antioxidant activities
Titled analogues 4a–j were studied to check their radical scav-
enging efficacies as antioxidants in DPPH and ABTS bioassay,
and the results are summarized in Table 1. The presence of dif-
ferent functional groups as alkyl, trifluoroalkoxy, trifluo-
romethyl, halo (F, Cl) and nitro led to the variety of
antioxidant activity patterns for the resultant molecules. In
general, title analogues represented better activity with IC50s
ranging from 12.17 ± 0.37–23.86 ± 3.47 lg/mL and 4.644
± 0.02–12.96 ± 0.30 lg/mL in DPPH and ABTS bioassay,
respectively than parent berberine with 33.16 ± 1.60 lg/mL
and 86.29 ± 2.11 lg/mL of IC50s in respective bioassay.
Analogue 4e and 4f with electron withdrawing and highlyelectronegative fluorine atom on the piperazine entity attached
to the berberine ring presented most effective radical scaveng-
ing potential in DPPH assay with around 12.17 lg/mL of
IC50s, comparable to that of control drug ascorbic acid at
10.75 lg/mL and far better than berberine at 33.16 lg/mL.
Also, compound 4f also exhibited significant antioxidant
power in ABTS assay with 4.644 lg/mL of IC50, which was
further comparable to that of the ascorbic acid standard at
5.760 lg/mL. A compound (4d) with electron withdrawing
chlorine atom presented an appreciable level of radical scav-
enging activity with IC50s, 12.23 ± 0.03 lg/mL and 5.817
± 0.04 lg/mL in DPPH and ABTS assay, respectively and
were nearer to that of control ascorbic acid. All compounds
exhibited a tremendous level of antioxidant power in ABTS
assay when compared to results appeared in the DPPH assay
in contrast with the antioxidant power of berberine. Hence,
compounds with halogen functionality 4d–4f can be considered
to have an appreciable level of antioxidant power in the
respective assay. Rest of the set of compounds showed
good to moderate level of radical scavenging power when com-
pared to control ascorbic acid. In terms of functional group
presence and activity relationships, the antioxidant efficacies
of the final analogues can be ordered as F > Cl > NO2 >
CH3 > OCF3 > CF3.
FRAP assay was adapted to inspect the Fe+3 ion reducing
capabilities of final berberine-piperazine Mannich bases. An
Table 1 Screening results of DPPH, ABTS and FRAP radical
scavenging activity of berberine derivatives (4a–j).
N+
O
O
OH
OCH3
Cl-
N
N
R
Compounds R IC50 lg/mL± SD
a FRAP
(10 lg/mL)d
DPPHb ABTSc
4a 4-CH3 19.33 ± 1.12 12.96 ± 0.30 2.221 ± 0.26
4b 2-Cl 16.89 ± 0.28 6.327 ± 0.16 1.907 ± 0.57
4c 3-Cl 21.30 ± 2.28 5.280 ± 0.50 0.781 ± 1.23
4d 4-Cl 12.23 ± 0.03 5.817 ± 0.04 1.743 ± 0.62
4e 2-F 12.17 ± 0.37 6.461 ± 0.08 1.399 ± 0.72
4f 4-F 12.17 ± 1.45 4.644 ± 0.02 0.002 ± 1.05
4g 4-OCF3 21.13 ± 1.68 11.61 ± 0.52 0.005 ± 1.32
4h 4-CF3 23.86 ± 3.47 8.067 ± 0.12 0.004 ± 0.56
4i 2-NO2 16.95 ± 1.03 8.183 ± 0.05 0.004 ± 0.48
4j 4-NO2 15.07 ± 1.38 8.795 ± 0.23 0.005 ± 0.73
Berberine – 33.16 ± 1.60 86.29 ± 2.11 0.001 ± 0.66
Ascorbic acid – 10.75 ± 0.66 4.760 ± 0.05 2.140 ± 0.78
a Antioxidant activities are shown as IC50 values in lg/mL. All
assays were carried out in triplicate, and the results expressed as
an average ± standard deviation.
b DPPH= 2,2-diphenyl-1-picrylhydrazyl.
c ABTS = 2,20-azino-bis-3-ethylbenzthiazoline-6-sulphonic acid.
d FRAP= ferric reducing ability of plasma.
Table 2 In vitro anticancer activity of synthesized compounds
against Hela cancer cell and their toxicity.
N+
O
O
OH
OCH3
Cl-
N
N
R
Compounds R IC50 lg/ml± SD
a CC50 lg/ml ± SD
b TIc
Hela MDCK
4a 4-CH3 4.353 ± 0.12 142.4 ± 0.04 32.71
4b 2-Cl 5.412 ± 0.06 147.8 ± 1.53 27.31
4c 3-Cl 3.983 ± 0.07 144.7 ± 0.76 36.33
4d 4-Cl 4.243 ± 0.03 194.2 ± 1.92 45.77
4e 2-F 5.876 ± 0.11 126.1 ± 1.33 21.46
4f 4-F 4.420 ± 0.02 139.3 ± 0.73 31.52
4g 4-OCF3 5.643 ± 0.05 159.2 ± 2.28 28.21
4h 4-CF3 4.255 ± 0.05 118.1 ± 1.07 27.76
4i 2-NO2 5.972 ± 0.05 129.1 ± 2.20 21.62
4j 4-NO2 5.952 ± 0.16 140.9 ± 2.23 23.67
Berberine – 4.499 ± 0.08 113.8 ± 0.51 25.29
a Anticancer activities are shown as IC50 values in lg/mL. All
assays were carried out in triplicate, and the results expressed as an
average ± standard deviation.
b CC50-cytotoxicity concentration of 50%.
c TI-therapeutic index.
42 B. Mistry et al.antioxidant compound has reductive capabilities and is
evaluated by Fe+3 to Fe+2 transformation upon releasing an
electron in the presence of test compounds. Therefore, the con-
centration of Fe+2 can be monitored by measuring the forma-
tion of Fe+2-tripyridyltriazine complex with blue colour. The
higher the absorbance of the compounds indicated greater
reducing power. Compounds 4a–j exerted absorption value
ranging from 0.002 ± 1.05 nm to 2.221 ± 0.26 nm. The
scaffolds which reduced metal ion complexes to their lower
oxidation state in FRAP assay were 4a with electron releasing
methyl functional group exhibiting 2.221 nm of absorption
level as well as two another analogues (4b and 4d) with
electron withdrawing chlorine groups with 1.907 nm and
1.743 nm of absorption levels. The results of FRAP assay of
these analogues are comparable to that of control compound
ascorbic acid having absorption value of 2.140 nm in FRAP
assay. Compounds 4f–4j was found inactive in FRAP assay
as compared to ascorbic acid and were of equal potency as par-
ent berberine. It can be stated that in FRAP assay, an opposite
trend of results appear when compared to other two antioxi-
dant assays, as compound 4a that was least active in FRAP
and ABTS assay furnished potent activity in FRAP assay.
The rest of the compounds showed lower absorbance ascompared to the standard but were of high efficacies when
compared to berberine.
3.2.2. Anticancer activities
Inhibitory efficacies of the cervical cancer cell line growth of
compound 4a–j were studied using sulforhodamine B (SRB)
bioassay and the results are presented in Table 2 for Hela cell
lines and Table 3 for Caski cell lines. In terms of therapeutic
indices (TIs), it is worth mentioning that all compounds exhib-
ited a reasonable level of anticancer potential against Hela and
Caski cell lines when compared to the therapeutic index of
parent compound berberine. Compounds 4a–j furnished
IC50s in the range 3.983 ± 0.07 to 5.972 ± 0.05 lg/mL with
a low level of cytotoxicity with CC50s 118.1 ± 1.07 to 194.2
± 1.92 lg/mL against Hela cell lines thereby establishing sig-
nificant therapeutic indices better than berberine. A compound
4d with electron withdrawing chlorine atom attached to the
para position of the phenyl ring of piperazine moiety signifies
highest anticancer effects against Hela cell lines with 4.243
± 0.03 lg/mL of IC50, 194.2 ± 1.92 lg/mL of CC50 with
45.77 of TI. In addition, an another analogue (4c) with
3-chlorophenyl piperazine ring attached via Mannich base
Table 3 In vitro anticancer activity of synthesized compounds
against Caski cancer cell and their toxicity.
N+
O
O
OH
OCH3
Cl-
N
N
R
Compounds R IC50 lg/ml ± SD
a CC50 lg/ml ± SD
b TIc
Caski MDCK
4a 4-CH3 5.003 ± 0.25 142.4 ± 0.04 28.46
4b 2-Cl 4.353 ± 0.10 147.8 ± 1.53 33.95
4c 3-Cl 4.920 ± 0.13 144.7 ± 0.76 29.41
4d 4-Cl 6.977 ± 0.31 194.2 ± 1.92 27.83
4e 2-F 4.623 ± 0.23 126.1 ± 1.33 27.28
4f 4-F 5.777 ± 0.19 139.3 ± 0.73 24.11
4g 4-OCF3 4.979 ± 0.14 159.2 ± 2.28 31.97
4h 4-CF3 4.821 ± 0.15 118.1 ± 1.07 24.50
4i 2-NO2 4.670 ± 0.13 129.1 ± 2.20 27.64
4j 4-NO2 4.560 ± 0.34 140.9 ± 2.23 30.90
Berberine – 5.643 ± 0.11 113.8 ± 0.51 20.17
a Anticancer activities are shown as IC50 values in lg/mL. All
assays were carried out in triplicate, and the results expressed as an
average ± standard deviation.
b CC50-cytotoxicity concentration of 50%.
c TI-therapeutic index.
Berberine moieties as anticancer and antioxidant effects 43functionality to the berberine ring exerted the second highest
level of Hela cell line inhibitory potential with 3.983
± 0.07 lg/mL of IC50, 144.7 ± 0.76 lg/mL of CC50 with
36.33 of TI. Compound 4a with alkyl, 4b with chlorine, 4f with
electronegative fluorine atom, 4g and 4h with trifluoro func-
tionality expressed 32.71, 27.31, 31.52, 28.21 and 27.76 of ther-
apeutic indices, better than that of berberine at 25.29 against
Hela cervical cancer cell lines. A compound with a nitro func-
tional group (4i and 4j) appeared with diminished anticancer
potential against Hela cell lines than that of berberine. An
opposite trend of anticancer action was observed while studying
cancerous cell inhibitory potential of compounds 4a–j against
cervical cancer cell line Caski. For example, compound 4j with
para-nitrophenyl piperazine moiety demonstrated high levels
of anti Caski cell line potency with IC50 4.560 ± 0.34 lg/mL
and showed tolerable cytotoxicity of 140.9 ± 2.23 lg/mL
thereby furnished 30.90 of TI, comparable to that of berberine
at 20.17. However, the most potent compound (4b) against
Caski cell line was with 2-chlorophenyl piperazine entity,
having 4.353 ± 0.10 of IC50, 147.8 ± 1.53 of CC50 and
33.95 of the therapeutic index. Moreover, a compound with
electronegative trifluoromethoxy functional group presented
the second highest action against the Caski cell line with
4.979 ± 0.14 of IC50, 159.2 ± 2.28 of CC50 and 31.97
of the therapeutic index. All the final compounds exhibitedbetter therapeutic indices against the Caski cell line than
berberine itself.4. Conclusion
A Mannich base series linking different EWD and ED func-
tional groups bearing piperazine entities to the natural alkaloid
substance berberine was constructed and examined for their
in vitro antioxidant and anticancer potential. Overall, results
of FRAP, DPPH and ABTS bioassay for the antioxidant
activity and SRB bioassay against Hela and Caski cell lines
of cervical cancer activity were quite fascinating when com-
pared to results obtained for the parent berberine compound.
Final Mannich bases with the chlorine and fluorine functional
group presented significant radical scavenging effects in DPPH
and FRAP assays, whereas those with alkyl functionality
exercised a reasonable level of Fe+3 reducing power in the
FRAP assay. Furthermore, the anticancer potential of
chlorinated analogues was tremendous against Hela and Caski
cell lines in addition to the reasonable level of activity observed
for those analogues bearing nitro and trifluoromethoxy func-
tional groups. Thus, results are worth stating that placement
of different functional groups on the moiety attached to the
berberine may result in positively enhanced anticancer and
antioxidant effects. Overall, title Mannich bases appeared with
better pharmacological efficacies in all the bioassays tested in
this study when compared to the parent compound berberine
and control drugs hence proving the rationalization of the
work worth considering.
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